$115MSeries C, 20 November 2025
Funds clinical trials of ANPD001, manufacturing scale-up and its iPSC pipeline.
- Amount
- $115M
- Stage
- Series C
- Announced
- 20 November 2025
- Lead
- OrbiMed
- Other investors
- ARCH Venture Partners, Frazier Life Sciences, Revelation Partners, Kite (Gilead), Balyasny Asset Management, Cormorant Asset Management, Prebys Ventures
- Use of funds
- Funds clinical trials of ANPD001, manufacturing scale-up and its iPSC pipeline.
- Checked
- Announced by the company
- Sources
- Aspen Neuroscience Announces $115 Million Series C Financing to Accelerate Personalized Cell Therapy Programs aspenneuroscience.com
Aspen Neuroscience Announces $115 Million Series C Financing to Accelerate Personalized Cell Therapy Programs news.google.com